Literature DB >> 3530610

The combined effects of two pairs of mediators, adenosine with methacholine and prostaglandin D2 with histamine, on airway calibre in asthma.

C C Hardy, P Bradding, C Robinson, S T Holgate.   

Abstract

Mediators released from mast cells and secondary effector cells in the airways contribute to bronchoconstriction of allergic asthma. This study investigates methods for defining the effect of two inflammatory mediators on airway calibre in asthma. In an initial study on three asthmatic subjects, subconstrictor (subthreshold) concentrations of two mast cell derived mediators, histamine and prostaglandin (PG) D2, produced similar displacement to the left of a histamine concentration-specific airways conductance (sGaw) response curve. With both agonists enhancement of histamine-induced bronchoconstriction was greater at low histamine concentrations. Since potentiation of histamine-induced bronchoconstriction was independent of the class of subconstrictor agent given, it is likely to represent a physiological rather than a pharmacological interaction. During provoked asthma different constrictor mediators are likely to be released simultaneously into the airways. A method was therefore devised to investigate the combined effect of equiconstrictor concentrations of two mediators on airway calibre. Two pairs of inhaled bronchoconstrictor agonists were chosen for study: adenosine with methacholine and PGD2 with histamine. For each agonist, concentration-sGaw response curves were constructed, from which were derived the provocation concentrations of agonist causing a 25% fall in sGaw from baseline (PC25) and required to further this to 50% (PC50-25). On separate days, eight subjects received paired inhalations of methacholine-adenosine, methacholine-methacholine and adenosine-adenosine. The concentration used for the first inhalation was the PC25 value and for the second inhalation the PC50-25 value. Before, immediately after the first inhalation, and at regular intervals after the second inhalation, sGaw was followed for 30 min.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3530610     DOI: 10.1042/cs0710385

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  7 in total

1.  Abolition of methacholine induced bronchoconstriction by the hyperventilation of exercise or volition.

Authors:  S Freedman; R Lane; M K Gillett; A Guz
Journal:  Thorax       Date:  1988-08       Impact factor: 9.139

Review 2.  Antihistamines in the treatment of asthma.

Authors:  S T Holgate
Journal:  Clin Rev Allergy       Date:  1994

3.  Adenosine influences myeloid cells to inhibit aeroallergen sensitization.

Authors:  Hong Pei; Joel Linden
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-03-25       Impact factor: 5.464

4.  The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations.

Authors:  S L Johnston; P G Bardin; J Harrison; W Ritter; J R Joubert; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1992-11       Impact factor: 4.335

5.  Effect of methacholine induced bronchoconstriction on the pulmonary distribution and plasma pharmacokinetics of inhaled sodium cromoglycate in subjects with normal and hyperreactive airways.

Authors:  R Richards; A Haas; S Simpson; A Britten; A Renwick; S Holgate
Journal:  Thorax       Date:  1988-08       Impact factor: 9.139

6.  Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma.

Authors:  J Britton; S P Hanley; H V Garrett; J W Hadfield; A E Tattersfield
Journal:  Thorax       Date:  1988-04       Impact factor: 9.139

7.  The reproducibility and effect on non-specific airway responsiveness of inhaled prostaglandin D2 and leukotriene D4 in asthmatic subjects.

Authors:  R Wood-Baker; G I Town; B Benning; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1995-02       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.